Literature DB >> 19380135

Mannose binding lectin deficiency and triglyceride-rich lipoprotein metabolism in normolipidemic subjects.

A Alipour1, A J H H M van Oostrom, J P H Van Wijk, C Verseyden, H W M Plokker, J W Jukema, A J Rabelink, M Castro Cabezas.   

Abstract

Mannose binding lectin (MBL) is one of the three initiators of complement activation and is therefore closely linked to inflammation. MBL deficiency has been associated with the generation of atherosclerosis. Since atherosclerosis, the complement system and postprandial lipemia are linked to inflammation, we studied postprandial lipoprotein metabolism in MBL deficiency. An observational study was carried out in 107 volunteers (21% MBL deficient). Classical cardiovascular risk factors were not different between subjects with and without MBL deficiency. Oral fat loading tests in 8 MBL deficient and 14 MBL sufficient subjects showed similar postprandial triglyceride, free fatty acid, hydroxybutyric acid and complement component 3 concentrations. MBL deficient subjects had 2.4 times lower postprandial Sf>400 (chylomicron)-apoB48 concentrations, but in contrast a 2-3.5 times increased Sf 60-400 (VLDL1-TG) and Sf 60-400-apoB100 response. MBL activity was inversely related to the postprandial Sf 60-400-TG increase. Despite lower postprandial Sf>400-apoB48 concentrations, MBL deficient subjects show an accumulation of Sf 60-400 lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380135     DOI: 10.1016/j.atherosclerosis.2009.03.007

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1.

Authors:  Boudewijn Klop; Pieter van der Pol; Robin van Bruggen; Yanan Wang; Marijke A de Vries; Selvetta van Santen; Joseph O'Flynn; Gert-Jan M van de Geijn; Tjin L Njo; Hans W Janssen; Peter de Man; J Wouter Jukema; Ton J Rabelink; Patrick C N Rensen; Cees van Kooten; Manuel Castro Cabezas
Journal:  J Biol Chem       Date:  2014-10-27       Impact factor: 5.157

2.  Low Mannose-Binding Lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort study.

Authors:  Machiel A Siezenga; Prataap K Chandie Shaw; Mohamed R Daha; Ton J Rabelink; Stefan P Berger
Journal:  Cardiovasc Diabetol       Date:  2011-07-05       Impact factor: 9.951

3.  Mannose-binding lectin deficiency is associated with myocardial infarction: the HUNT2 study in Norway.

Authors:  Inga Thorsen Vengen; Hans O Madsen; Peter Garred; Carl Platou; Lars Vatten; Vibeke Videm
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

4.  Mannose-Binding Lectin Levels and Carotid Intima-Media Thickness in Type 2 Diabetic Patients.

Authors:  Miklós Káplár; Shah Sweni; Julianna Kulcsár; Barbara Cogoi; Regina Esze; Sándor Somodi; Mária Papp; László Oláh; Mária Tünde Magyar; Katalin Szabó; Katalin Réka Czuriga-Kovács; Jolán Hársfalvi; György Paragh
Journal:  J Diabetes Res       Date:  2015-11-10       Impact factor: 4.011

Review 5.  Dyslipidemia in obesity: mechanisms and potential targets.

Authors:  Boudewijn Klop; Jan Willem F Elte; Manuel Castro Cabezas
Journal:  Nutrients       Date:  2013-04-12       Impact factor: 5.717

Review 6.  Mannan-binding lectin in cardiovascular disease.

Authors:  Izabela Pągowska-Klimek; Maciej Cedzyński
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

7.  Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients.

Authors:  Felix Poppelaars; Mariana Gaya da Costa; Stefan P Berger; Solmaz Assa; Anita H Meter-Arkema; Mohamed R Daha; Willem J van Son; Casper F M Franssen; Marc A J Seelen
Journal:  J Transl Med       Date:  2016-08-05       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.